NagaChalasaniMD

PubMed

• PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic-associated steatotic liver disease.
  Eduardo Vilar-Gomez, Katherine P Yates, Laura A Wilson, James Tonascia, Naga Chalasani, Rohit Loomba, Anna Mae Diehl, Brent A Neuschwander-Tetri, Srinivasan Dasarathy,...> ;Hepatology. 2024 Apr 23
• Effects of Food Insecurity on Hepatic Steatosis and Fibrosis in People With HIV.
  Eduardo Vilar-Gomez, Jordan E Lake, Holly Crandall, Laura A Wilson, , Ani Kardashian, Audrey Lloyd, Susanna Naggie, Mark S Sulkowski, Tinsay Woreta, Rohit Loomba, Rich...> ;Clinical Gastroenterology and Hepatology. 2024 Apr 5
• Lean body mass index is a marker of advanced tumor features in patients with hepatocellular carcinoma.
  Jing Zhao, Milin Patel, Hieu Minh Nguyen, Maggie McCarter, Heather Burney, Carla Kettler, Andrew Scott deLemos, Banks Kooken, Karan Mathur, Areej Mazhar, Naga Chalasan...> ;World Journal of Hepatology. 2024 Mar 27
• Drug-induced Liver Injury from Hormonal and Non-hormonal Therapies: Insights from a Large Case Series.
  Raj Vuppalanchi, Naga Chalasani> ;Journal of Clinical and Experimental Hepatology. 2024 Mar 19
• Non-Hispanic Black persons with nonalcoholic fatty liver disease have lower rates of advanced fibrosis, cirrhosis, and liver-related events even after controlling for ...
  Niharika Samala, Yuchen Xin, Laura A Wilson, Katherine Yates, Rohit Loomba, Jay H Hoofnagle, Naga Chalasani> ;The American Journal of Gastroenterology. 2024 Mar 14
• Editorial: Updated epidemiology of steatotic liver disease in people with HIV in the United States-Authors' reply.
  Gawrieh, S., Sulkowski, M., Chalasani, N., Loomba, R., Loomba, R.> ;Alimentary Pharmacology & Therapeutics. 2024 Mar 1
• Amiodarone and Dronedarone Causes Liver Injury with Distinctly Different Clinical Presentations.
  Alexander Pop, Dina Halegoua-DeMarzio, Huiman Barnhart, David Kleiner, Mark Avigan, Jiezhun Gu, Naga Chalasani, Jawad Ahmad, Robert J Fontana, William Lee, A Sidney Ba...> ;Digestive Diseases and Sciences. 2024 Apr 1
• Occult liver disease: A multinational perspective.
  Paulina Vidal-Cevallos, Nayelli Flores-García, Norberto C Chávez-Tapia, Naga P Chalasani> ;Annals of Hepatology. 2024 Feb 12
• 1 citations
  Primary Sclerosing Cholangitis Limited to Intrahepatic Bile Ducts Has Distinctly Better Prognosis.
  Vijay S Are, Mark A Gromski, Fatih Akisik, Eduardo Vilar-Gomez, Craig Lammert, Marwan Ghabril, Raj Vuppalanchi, Naga Chalasani> ;Digestive Diseases and Sciences. 2024 Apr 1
• 1 citations
  Randomized trial of anakinra plus zinc vs. prednisone for severe alcohol-associated hepatitis.
  Samer Gawrieh, Srinivasan Dasarathy, Wanzhu Tu, Patrick S Kamath, Naga P Chalasani, Craig J McClain, Ramon Bataller, Gyongyi Szabo, Qing Tang, Svetlana Radaeva, Bruce ...> ;Journal of Hepatology. 2024 May 1
• 1 citations
  Role of Spleen Stiffness Measurement in the Evaluation of Metabolic Dysfunction-Associated Steatotic Liver Disease.
  Elizabeth E Williams, Andrea Mladenovic, Dheeksha Ranginani, Regina Weber, Niharika Samala, Samer Gawrieh, Eduardo Vilar-Gomez, Naga Chalasani, Raj Vuppalanchi> ;Digestive Diseases and Sciences. 2024 Apr 1
• Diagnostic Ability of Simple Noninvasive Blood Tests to Predict Increased Liver Stiffness in People Living With HIV and Steatotic Liver Disease.
  Loomba, R., Richard K Sterling, Eduardo Vilar-Gomez, Laura A Wilson, Rohit Loomba, Samer Gawrieh, Jennifer Price, Susanna Naggie, Jordan E Lake, Sonya Heath, James Ton...> ;The American Journal of Gastroenterology. 2024 Mar 20
• Response to Rollins and Abaza.
  Phillips, E., Nicoletti, P., Chalasani, N.> ;The American Journal of Gastroenterology. 2024 Feb 1
• Hospital frailty risk score is superior to legacy comorbidity indices for risk adjustment of in-hospital cirrhosis cases.
  Knapp, S., Desai, A., Parvataneni, S., Nephew, L., Chalasani, N., Ghabril, M., Orman, E.> ;JHEP Reports. 2024 Jan 1
• 2 citations
  Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States.
  Vilar-Gomez, E., Wilson, L., Gawrieh, S., Woreta, T., Lake, J., Price, J., Naggie, S., Sterling, R., Heath, S., Corey, K., Cachay, E., Ajmera, V., Tonascia, J., Sulkow...> ;Alimentary Pharmacology & Therapeutics. 2024 Mar 1
• Age, BMI, and Type 2 Diabetes Modify the Relationship Between PNPLA3 and Advanced Fibrosis in Children and Adults With NAFLD.
  Loomba, R., Chaowapong Jarasvaraparn, Eduardo Vilar-Gomez, Katherine P Yates, Laura A Wilson, Brent Neuschwander-Tetri, Rohit Loomba, Oscar Cummings, Miriam Vos, Stavr...> ;Clinical Gastroenterology and Hepatology. 2024 May 1
• Severe hepatic encephalopathy with mechanical ventilation may inform waitlist priority in acute liver failure: A UNOS database analysis.
  Jiayi Ma, James E Slaven, Lauren Nephew, Kavish R Patidar, Archita P Desai, Eric Orman, Chandrashekhar Kubal, Naga Chalasani, Marwan Ghabril> ;Clinical Transplantation. 2024 Jan 1
• Incidence, clinical characteristics, and risk factors associated with recurrent alcohol-associated hepatitis.
  Kavish R Patidar, Maria Guarnizo Ortiz, James E Slaven, Lauren D Nephew, Eduardo Vilar Gomez, Carla D Kettler, Marwan S Ghabril, Archita P Desai, Eric S Orman, Naga Ch...> ;Hepatology Communications. 2023 Dec 1
• 1 citations
  The Safe Use of Analgesics in Patients with Cirrhosis: A Narrative Review.
  Jiayi Ma, Einar Stefán Björnsson, Naga Chalasani> ;The American Journal of Medicine. 2024 Feb 1
• Clinical characteristics and prognosis of hospitalized patients with moderate alcohol-associated hepatitis.
  Maria Gaurnizo-Ortiz, Lauren D Nephew, Eduardo Vilar-Gomez, Carla D Kettler, James E Slaven, Marwan S Ghabril, Archita P Desai, Eric S Orman, Naga Chalasani, Samer Gaw...> ;Liver International. 2024 Jan 1
• Liver biopsy for assessment of suspected drug-induced liver injury in metabolic dysfunction-associated steatohepatitis clinical trials: Expert consensus from the Liver...
  Melissa Palmer, David E Kleiner, Zachary Goodman, Elizabeth Brunt, Mark I Avigan, Arie Regev, Paul H Hayashi, James H Lewis, Ruby Mehta, Stephen A Harrison, Massimo Si...> ;Alimentary Pharmacology & Therapeutics. 2024 Jan 1
• A 68-Year-Old Woman With Unexplained Liver Enzyme Elevation and Active Chronic Hepatitis: Beware of Drug-Induced Autoimmune-Like Hepatitis.
  Lily Dara, Marwan Ghabril, Naga Chalasani, Phillips, E., Kleiner, D.> ;Gastroenterology. 2024 Feb 1
• 2 citations
  A composite score using quantitative magnetic resonance cholangiopancreatography predicts clinical outcomes in primary sclerosing cholangitis.
  Raj Vuppalanchi, Vijay Are, Alison Telford, Liam Young, Sofia Mouchti, Carlos Ferreira, Carla Kettler, Mark Gromski, Fatih Akisik, Naga Chalasani> ;JHEP Reports. 2023 Oct 1
• Dynamic Alterations to Hepatic MicroRNA-29a in Response to Long-Term High-Fat Diet and EtOH Feeding.
  Tiebing Liang, Janaiah Kota, Kent E Williams, Romil Saxena, Samer Gawrieh, Xiaoling Zhong, Teresa A Zimmers, Naga Chalasani> ;International Journal of Molecular Sciences. 2023 Sep 26
• 2 citations
  Vancomycin-Induced Liver Injury, DRESS, and HLA-A∗32:01.
  Bilal A Asif, Christopher Koh, Elizabeth J Phillips, Jiezhun Gu, Yi-Ju Li, Huiman Barnhart, Naga Chalasani, Robert J Fontana, Paul H Hayashi, Victor J Navarro, Jay H H...> ;The Journal of Allergy and Clinical Immunology. in Practice. 2024 Jan 1
• Join now to see all

Journal Articles

• In a Pilot Study, Reduced Fatty Acid Desaturase 1 Function Was Associated with Nonalcoholic Fatty Liver Disease and Response to Treatment in Children  
  Jingmei Lin, Naga P Chalasani, Nature
• Liver Stiffness Measurements in Patients with Non‐Cirrhotic Portal Hypertension – the Devil Is in the Details  
  Niharika Samala, Raj Vuppalanchi, Naga Chalasani, Hepatology
• Common Variation near IRF6 Is Associated with IFN-Β-induced Liver Injury in Multiple Sclerosis  
  Joshua C Denny, Zongqi Xia, Naga Chalasani, Nature
• Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the drug induced liver injury network  
  Hayashi PH, Barnhart HX, Fontana RJ, Chalasani N, Davern TJ, Talwalkar JA, Reddy KR, Stolz AA, Hoofnagle JC, Rockey DC, Liver Int, 1/24/2014
• Relationship between changes in serum keratin 18 fragments and changes in liver histology in adults and in children with nonalcoholic fatty liver disease  
  Vuppalanchi R, Jain AK, Deppe R, Yates K, Comerford M, Yates K, Masuoka HC, Neuschander-Tetri B, Loomba R, Brunt EM, Kleiner DE, Molleston JP, Schwimmer J, Lavine JE, ..., Clin Gastroenterol Hepatol, 1/17/2014
• Drug induced liver injury due to statins: experience of the US Drug Induced Liver Injury Network  
  Russo MW, Hoofnagle JH, Gu J, Fontana RJ, Barnhart H, Kleiner DE, Chalasani N, Bonkovsky HL, Hepatology, 1/2/2014
• Trials and tribulations in drug development for nonalcoholic steatohepatitis (Editoria)  
  Sanyal AJ, Chalasani N, Clinical Gastroenterology and Hepatology, 1/1/2014
• HIV-coinfection profoundly alters intrahepatic chemokine but not inflammatory cytokine profiles in HCV-infected subjects  
  Hu S, Ghabril M, Amet T, Hu N, Dyrd D, Vuppalanchi R, Saxena R, Desaif M, Johnson R, Gupta S, Chalasani N, Yu Q, PLoS, 1/1/2014
• Serum hepcidin levels are associated with obesity but not liver disease  
  Vuppalanchi R, Troutt JS, Konrad RJ, Ghabril M, Saxena R, Bell LN, Kowdley KV, Chalasani N, Obesity, 1/1/2014
• Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations  
  Kleiner DE, Chalasani N, Lee W, Fontana R, Bonkovsky HL, Watkins PB, Hayashi P, Davern T, Navarro V, Reddy KR, et al, Hepatology, 1/1/2014
• Management of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver disease  
  Corey KE, Chalasani N, Clinical Gastroenterology and Hepatology, 1/1/2014
• There is substantial morbidity and mortality associated with idiosyncratic drug induced liver injury: results from the DILIN prospective study  
  Fontana RJ, Hayashi PH, Gu J, Reddy KR, Barnhart H, Watkins PB, Serrano J, Lee WM, Chalasani N, Stolz A, Davern T, Talwalkar JA, Gastroenterology, 1/1/2014
• IL-12/Th1 and IL-23/Th17 biliiary microenvironment in primary biliary cirrhosis: Implications for therapy  
  Yang CY, Ma X, Tsuneyama K, Takahashi T, Chalasani N, Yang GX, Leung PSC, Ansari AA, Wu L, Strauss R, Gershwin ME, Hepatology, 1/1/2014
• Genetic polymorphism of cytochrome P450 4F2, vitamin E and histological response in adults and children with nonalcoholic fatty liver disease who participated in PIVEN...  
  Athinarayan S, Wei R, Bai S, Traber MG, Yates K, Cummings OW, Molleston JP, Liu W, Chalasani N, PLoS ONE, 1/1/2014
• Endoscopic therapy with 2-octyl-cyanoacrylate for the treatment of gastric varices  
  Kahloon A, Chalasani N, Dewitt J, Liangpunsakul S, Vinayek R, Ghabril M, Chiorean M, Digestive Diseases and Sciences, 1/1/2014
• Nodular regenerative hyperplasia due to trastuzumab emtansine  
  Force J, Saxena R, Schneider B, Storniolo AM, Sledge GW, Chalasani N, Vuppalanchi R, J Clinical Oncology, 1/1/2014
• An integrated omics analysis of human liver tissue revealed a mechanistic pathway underlying the role of FADS1 in hepatic lipid accumulation  
  Wang L, Athinarayanan S, Chalasani N, Zhang M, Liu W, Hepatology, 1/1/2014
• Genetic control of hepatic PNPLA3 transcription and a high-risk haplotype identifies a modifier allele for 148M and a high risk haplotype supporting the gain-of-functi...  
  Liu W, Anstee QM, Wang X, Gamazon ER, Athinarayanan S, Liu YL, Darlay R, Cordell HJ, the FLIP investigators, Daly AK, Day CP, Chalasani N, Gastroenterology, 1/1/2014
• Serum metabolic signatures of primary biliary cirrhosis and primary sclerosing cholangitis  
  Bell LN, Comerford M, Vuppalanchi R, Chalasani N, Liver International, 1/1/2014
• Clinical and histopathologic features of azithromycin-induced liver injury  
  Martinez M, Vuppalanchi R, Fontana R, Stolz A, Kleiner DE, Watkins PB, Barnhart H, Hoofnagle J, Chalasani N, Clinical Gastroenterology and Hepatology, 1/1/2014
• Obeticholic acid for nonalcoholic steatohepatitis: a randomized, placebo-controlled trial  
  Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek M, Chalasani N, Dasarathy S, e t al, New Engl J Med, 1/1/2014
• Drug Induced Liver Injury  
  Chalasani N & Hayashi PH (Co-editors), Seminars Liver Disease, 1/1/2014
• Drug-induced hepatic steatosis  
  Amacher DE, Chalasani N, Semin Liver Dis, 1/1/2014
• An assessment of statin liver safety - 2014 update  
  Bays H, Cohen DE, Chalasani NP, Harrison SA, J Clin Lipidol, 1/1/2014
• The diagnosis and Management of idiosyncratic drug induced liver injury: Practice guideline by the American College of Gastroenterology  
  Chalasani N, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ on behalf of the American College of Gastroenterology, Am J Gastroenterology, 1/1/2014
• Join now to see all

Books/Book Chapters

• Drug Induced Liver Disease. 
  Vuppalanchi R, Chalasani NEditors: Kaplowitz N, DeLeve L.Marcel Dekker PublicationsEdition 3rd,2012
• Drug Induced Liver Injury: Epidemiology in the Western Countries. 
  Bell LN, Chalasani N2009
• Hepatology: A Textbook of Liver Disease. 
  Chapter: The Liver in Systemic Disease. 
  Chalasani N, Cummings OWEditors: Zakim D, Boyer TD.WB Saunders, Philadelphia, PAEdition 4th,2002
• Drug Induced Liver Disease. 
  Chapter: Hepatotoxicity due to cardiovascular and endocrinological drugs. 
  Bhardwaj S, Chalasani NEditors: Kaplowitz N, DeLeve L.Marcel Dekker Publications
• Evidence based Gastroenterology and Hepatology. 
  Chapter: Drug Induced Liver Injury. 
  Polson J, Chalasani NEditors: Younossi Z.Oxford PublicationsEdition 1st,
• Practical Gastroenterology and Hepatology. 
  Chapter: Drug Induced Liver Injury. 
  Bjornsson E, Chalasani NEditors: Talley N (Leader Editor), Lindor K and Vargas H.
• In Cecil's Text Book of Medicine. 
  Chapter: Alcoholic liver disease & Nonalcoholic fatty liver disease. 
  Chalasani NEditors: Ausiello & Goldman.Edition 23rd,
• Join now to see all

Abstracts/Posters

• Automatic quantification of liver histology in NAFLD. A promising tool to facilitate better histological characterization.
  Vanderbeck S, Bockhorst J, Komorowski R, Kleiner DE, Chalasani NP, Gawrieh S, Gastroenterology, DDW, 1/1/2014
• Little evidence for serious outcome in patients with chronic liver disease receiving potentially hepatotoxic drugs.
  Bjornsson E, Einarsdottir R, Jacobsen E, Chalasani NP, Gastroenterology, DDW, 1/1/2014
• Idiosyncratic drug induced liver injury in the United States: a report of 1257 prospectively enrolled patients.
  Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, et al, American College of Gastroenterology 2014 Annual Meeting, 1/1/2014
• Drug induced liver injury (DILI) in patients with underlying liver disease has worse prognosis: results from the drug induced liver injury network (DILIN) prospective ...
  Chalasani N, Bonkovsky HL, Fontana RJ, Gu J, Hayashi P, et al, AASLD Annual Meeting, 1/1/2014
• A comprehensive assessment of environmental exposures among 1000 North American primary sclerosing cholangitis patients with and without inflammatory bowel disease.
  Eaton JE, Juran BD, Atkinson EJ, Schlicht EM, Xie X, Andrade M, Luketic VA, Odin J, Koteish AA, Kowdley KV, Chopra KB, Hirshfield GM, Chalasani NP, Lazaridis LN, AASLD, 1/1/2014
• Disturbed sleep in highly prevalent in patients with cirrhosis and is independently associated with poor quality of life.
  Jackson M, Orman ES, Vuppalanchi R, Chalasani N, Ghabril M, AASLD Annual Meeting, 1/1/2014
• Global serum metabolomic profiling identifies a distinct metabolomic signature in patients with cirrhosis who have altered sleep pattern.
  Ghabril M, Jackson M, Bell LN, Gunst PR, Ornam ES, Vuppalanchi R, Chalasani N, AASLD Annual Meeting, 1/1/2014
• Delirium is related to hepatic encephalopathy and is associated with poor outcomes in cirrhosis.
  Orman ES, Perkins A, Ghabril M, Khan BA, Chalasani N, Boustani MA, AASLD annual meeting, 1/1/2014
• Clinical characteristics and outcomes of acute alcoholic hepatitis - preliminary report from the Translation al Research and Evolving Alcoholic Hepatitis Treatment (TR...
  Liangpunsakul S, Shah V, Sanyal A, Katz B, Kamath P, Saberi B, Ren Z, Puri P, Chalasani N, Crabb DW, Radaeva S, AASLD annual meeting, 1/1/2014
• Do liver transplant centers need different bench marks for quality metrics for managing hospitalized patients with cirrhosis.
  Ghabril M, Kwo PY, Tector J, Agrawal S, Chalasani N, AASLD annual meeting, 1/1/2014
• Fibroblast growth factor 21 treatment improves atherogenic diet-induced liver injury and metabolic syndrome in Ossabaw miniature swine.
  Gawrieh S, Alloosh M, Sheridan R, Liang T, Masuoka MC, Chalasani N, Sturek M, AASLD annual meeting, 1/1/2014
• Autoimmune hepatitis with inflammatory bowel disease in distinct and may be more refractory to traditional treatment.
  Bailey B, Fischer M, Vuppalanchi R, Ghabril M, Gawrieh M, Orman ES, Chalasani N, Lammert C, ACG annual meeting, 1/1/2014
• Biochemical response is associated with improved survival in patients with autoimmune hepatitis and advanced disease.
  Baily B, Orman ES, Vuppalanchi R, Ghabril M, Gawrieh S, Chalasani N, Lammert C, AASLD annual meeting, 1/1/2014
• Urea cycle disorders in patients with cirrhosis and hepatic encephalopathy.
  Ghabril M, Gotur R, Weber R, Hainline B, Chalasani N, AASLD annual meeting, 1/1/2014
• Early phase 1 results of GR-MD-02, a galectin-3 inhibitor, in patients with NASH and advanced fibrosis.
  Harrison SA, Chalasani N, Lawitz E, Noureddin M, Sanyal A, Schiano T, Siddique M, Tetri B, Traber PG, AASLD annual meeting, 1/1/2014
• NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels.
  Corey KE, Vuppalanchi R, Wilson L, Cummings OW, Chalasani N, for the NASH CRN, AASLD Annual Meeting, 1/1/2014
• Profiles of serum microRNAs in acute drug-induced liver injury and their prognostic significance.
  Russo MW, Norton JB, Anderson W, Steurwald M, Barnhart H, Chalasani N, Fontana R, Hayashi P, Serrano J, Bonkosky HL, AASLD Annual Meeting, 1/1/2014
• Examination of dietary factors in autoimmune hepatitis utilizing social media and crowdsourcing.
  Comerford M, Chalasani N, Lammert C, AASLD Annual Meeting, 1/1/2014
• Portal vein thrombosis is a risk factor for early mortality and graft loss post liver transplantation: analysis of the UNOS database.
  Ghabril M, Kwo PY, Tector J, Lacerda M, Chalasani N, Agrawal S, AASLD Annual Meeting, 1/1/2014
• Cholestatic drug reactions are more likely to cause persistent liver injury and impaired quality of life during prolonged follow-up: results from the DILIN Prospective...
  Fontana RJ, Hayashi P, Reddy KR, Kleiner DE, Philips T, Barnhart H, Talwalkar J, Chalasani N, Lee W, Stolz A, Davern T, Watkins PB, Serrano J, Hoofnagle JH, AASLD Annual Meeting, 1/1/2014
• Genetic polymorphism of cytochrome P450 4F2 (CYP4F2) and histological response to vitamin E treatment in children and adults with nonalcoholic fatty liver disease.
  Dutta A, Chalasani N, DDW, 1/1/2013
• Changes in serum cytokeratin 18 levels significantly predict changes in liver histology in adults with nonalcoholic steatohepatitis.
  Vuppalanchi R, Deppe R, Yates K, Comerford M, Masuoka H, Tetri B, Loomba R, Brunt E, Kleiner D, Tonascia J, Chalasani N for the NASH CRN, DDW, 1/1/2013
• Novel genetic loci associated with steatohepatitis and fibrosis in Hispanic boys with nonalcoholic fatty liver disease.
  Lavine JE, Chalasani NP, Guo X, Kwon S, Schwimmer J, Molleston JP, Loomba R, Brunt EM, Chen IYD, Goodarzi M, Taylor KD, Yates KP, Unalp-Arida A, Rotter JI, DDW, 1/1/2013
• Mapping expression quantitative traits loci (eQTL) for PNPLA3gene identifies additional SNPs associated nonalcoholic fatty liver disease independent of rs738409.
  Wang X, Onjiko R, Anstee QM, Ratziu V, Liu YL, Cordell HJ, Darlay R, Day CP, Daly AK, Chalasani N, Liu W, EASL meeting, 1/1/2013
• Serum keratin fragment 18 (CK18) levels significantly predict changes in liver histology in children and adolescents with nonalcoholic fatty liver disease (NAFLD): Res...
  Jain AK, Deppe RB, Yates KP, Comerford M, Masuoka HC, Molleston JP, Schwimmer JB, Lavine JE, Brunt EM, Tonascia J, Kleiner DE, Chalasani NP, AASLD, 1/1/2013
• Join now to see all

Lectures

• Advances in Non-Alcoholic Fatty Liver Disease (NAFLD) 
  AGC 2018 Annual Scientific Meeting, Philadelphia, PA - 10/8/2018
• Initial Work-Up and Evaluation of a Patient With NAFLD 
  AGC 2018 Annual Scientific Meeting, Philadelphia, PA - 10/8/2018
• Vitamin D deficiency in Chronic Liver Disease. 
  1/1/2012
• Single Topic Symposium on Nonalcoholic Fatty Liver Disease. 
  Kolkata, India - 1/1/2012
• Nonalcoholic Fatty Liver Disease. 
  1/1/2011
• Vitamin E in NAFLD symposium. 
  Bethesda, MD - 1/1/2011
• Genetic basis of drug induced liver injury. 
  1/1/2011
• Annual Liver Course. 
  Charleston, SC - 1/1/2009
• Drug induced liver injury - Standardization of nomenclature and causality. 
  1/1/2008
• Using controlled clinical trials to learn more about acute drug-induced liver injury. 
  1/1/2008
• Drug Hepatotoxicity. 
  1/1/2007
• AGA-Duke GI series. 
  1/1/2007
• Annual Texas Hepatology Update . 
  San Antonio, TX, 2006, 2007 - 1/1/2007
• Portal Hypertension. 
  Atlanta, GA - 1/1/2007
• Meet the GI Experts. 
  1/1/2007
• An overview of Chronic Liver Disease and Cirrhosis. 
  1/1/2006
• Academic Hepatology Workshop. 
  1/1/2006
• Steatohepatitis. 
  Atlanta, GA - 1/1/2006
• Statin Hepatotoxicity. 
  1/1/2005
• Statin Toxicity (Liver Safety Panel). 
  Washington, DC - 1/1/2005
• Primary Sclerosing Cholangitis. 
  Bethesda, MD - 1/1/2005
• Drug Induced Liver Injury. 
  Atlanta, GA - 1/1/2005
• Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. 
  Baveno, Italy - 1/1/2005
• Recommendations of liver expert panel. 
  Washington, DC - 1/1/2005
• Drug-induced liver injury: Summary of a single topic clinical research conference. 
  Atlanta, GA - 1/1/2005
• Join now to see all

Other

• NAFLD and it management. 
  Chalasani N (Series Ed), Clinical Liver Disease, an electronic publication of the AASLD
  1/1/2012